Sola Dx develops and markets minimally invasive epigenetics based test for early cancer detection and prediction.
Sola Diagnostics has raised $417K in total funding. The most recent round was Seed. The last funding was announced in February 2025.
Sola Diagnostics's investors include FPS-Holding.
Sola Diagnostics is headquartered in Innsbruck, Austria.
Sola Dx develops and markets minimally invasive epigenetics based test for early cancer detection and prediction.
Sola Diagnostics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sola Diagnostics — Funding & Investors." VCBacked, February 20, 2025, https://www.vcbacked.co/company/sola-diagnostics. Accessed August 1, 2026.
VCBacked. (2025). Sola Diagnostics — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/sola-diagnostics
{{cite web |title=Sola Diagnostics — Funding & Investors |url=https://www.vcbacked.co/company/sola-diagnostics |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated